|
2026
|
Invention
|
Chimeric antigen receptor (car) comprising a cd19-binding domain.
There is provided a chimeric a... |
|
|
Invention
|
Treatment of light chain amyloidosis. The present disclosure relates to BCMA/CD19 CAR T-cell prod... |
|
|
Invention
|
Method for producing engineered cells expressing chimeric antigen receptors. A process for produc... |
|
|
Invention
|
Cell.
There is provided an effector immune cell which expresses a cell surface receptor or recep... |
|
2025
|
Invention
|
Anti trbc1 antigen binding domains.
The present disclosure relates to anti-TRBC1 antigen binding... |
|
|
Invention
|
Transcription system.
The present invention provides a transcription system which comprises: (a)... |
|
|
Invention
|
Cell.
A cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the ce... |
|
|
Invention
|
Signalling system.
The present invention provides a chimeric antigen receptor (CAR) system compr... |
|
|
Invention
|
Method. The present invention provides methods for selecting a bridging therapy for a patient hav... |
|
|
Invention
|
Chimeric antigen receptor.
The present invention provides a chimeric antigen receptor (CAR) comp... |
|
|
Invention
|
Treatment of autoimmune disease by co-expression of cd19-car and bcma-car. There is provided a me... |
|
|
Invention
|
Compositions and methods comprising engineered chimeric antigen receptor and modulator of car.
T... |
|
|
Invention
|
Methods.
The present invention relates to a chimeric antigen receptor (CAR) which comprises an a... |
|
|
P/S
|
Medical and veterinary preparations, namely, engineered T-cells for medical therapeutic purposes;... |
|
|
P/S
|
Medical and veterinary preparations for therapeutic
purposes; preparations for cell therapy; pre... |
|
|
P/S
|
Medical and veterinary preparations for the treatment of cancer, genetic conditions, immune respo... |
|
|
Invention
|
Chimeric cytokine receptor.
The present invention provides a chimeric cytokine receptor (CCR) co... |
|
|
Invention
|
Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ... |
|
2024
|
Invention
|
Retroviral and lentiviral vectors.
The present invention provides a retroviral or lentiviral vec... |
|
|
Invention
|
Chimeric antigen receptor.
The present invention provides a chimeric antigen receptor (CAR) whic... |
|
|
Invention
|
Bcma/cd19 car for treating multiple myeloma.
The present disclosure relates to BCMA/CD19 CAR T-c... |
|
|
Invention
|
Cell.
The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a... |
|
|
P/S
|
Downloadable mobile applications for use in enabling healthcare professionals and patients to acc... |
|
|
P/S
|
Downloadable mobile applications for use in enabling
healthcare professionals and patients to ac... |
|
|
Invention
|
Method for producing engineered immune cells. The present invention provides a process for produc... |
|
|
Invention
|
Products and methods for treating autoimmune diseases. The present invention relates to a chimeri... |
|
|
Invention
|
Products and methods for treating autoimmune diseases |
|
|
Invention
|
T-cell receptor constant region 1 antibody or t-cell receptor constant region 2 antibody.
The pr... |
|
|
Invention
|
Methods and cell compositions. There is provided an anti-GD2 CAR T cell composition, a method for... |
|
|
Invention
|
Anti-tcrb1 and anti-tcrb2 t cells. A method of preparing a population of genetically modified cel... |
|
|
Invention
|
Method for determining a vector copy number in a biological sample using digital droplet pcr (dd-... |
|
|
Invention
|
Method. The present invention provides a method of determining the relative potency of a viral ve... |
|
|
Invention
|
Chimeric transmembrane protein. The present invention relates to a chimeric transmembrane protein... |
|
|
Invention
|
Treatment of trbc1-positive t cell malignancies.
The present disclosure relates to the treatment... |
|
|
Invention
|
Treatment of trbc1-positive t cell malignancies. The present disclosure relates to the treatment ... |
|
|
Invention
|
Chimeric antigen receptors directed against trbc1 and trbc2. The present invention provides a chi... |
|
|
Invention
|
Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia |
|
|
Invention
|
Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia. The present... |
|
|
Invention
|
Chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma.
The present inve... |
|
|
Invention
|
A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma. The present inv... |
|
|
Invention
|
A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma |
|
|
Invention
|
Nucleic acid construct.
The present invention provides a nucleic acid construct comprising: a fi... |
|
2023
|
Invention
|
Chimeric antigen receptor with spacers. The present invention provides a chimeric antigen recepto... |
|
|
Invention
|
Cell expressing a car and a transcription factor and its use.
The present invention provides a c... |
|
|
Invention
|
Chimeric antigen receptor.
Provision of a chimeric antigen receptor (CAR) comprising a disialoga... |
|
|
Invention
|
Vectors.
The present invention provides a kit of vectors for transducing an immune cell with mul... |
|
|
P/S
|
Medical and veterinary preparations for therapeutic purposes for the treatment of cancer, genetic... |
|
|
Invention
|
Method.
The present invention provides a method of preparing a population of genetically modifie... |
|
|
Invention
|
Cd19/c22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia.
T... |
|
2022
|
Invention
|
Chimeric cytokine receptor.
The present invention provides a chimeric cytokine receptor (CCR) wh... |
|
|
Invention
|
Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of disease... |
|
|
Invention
|
Generation of t-cells by direct reprogramming from fibroblasts and msc.
The invention relates to... |
|
2021
|
Invention
|
Cell.
The present invention relates to a cell which co-expresses: (i) a first chimeric antigen r... |
|
2020
|
Invention
|
Antigen-binding domain. The present disclosure relates to antigen-binding domains which bind the ... |
|
2015
|
P/S
|
Medical and veterinary preparations, namely, engineered T-cells for therapeutic purposes; prepara... |
